William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty

5 days ago 8

Sheryar Siddiq

Tue, November 25, 2025 astatine 7:39 AM CST 2 min read

uniQure N.V. (NASDAQ:QURE) ranks among the most oversold biotech stocks to put in. William Blair reaffirmed its Market Perform standing for uniQure N.V. (NASDAQ:QURE) connected November 11 portion the institution anticipates comments from regulators regarding its AMT-130 therapy. William Blair suggests that lobbyists and the aesculapian assemblage mightiness enactment unit connected regulators to negociate a speedy way to BLA submission, citing the beardown objective results released past period and the aboriginal involvement from patients and physicians for the Huntington’s illness medication.

The standing comes astatine a clip erstwhile uniQure N.V. (NASDAQ:QURE) is dealing with superior AMT-130 regulatory issues. The results from uniQure’s Phase 1/2 studies, which were antecedently thought to beryllium acceptable for a Biologics License Application (BLA), are nary longer regarded arsenic capable by the U.S. Food and Drug Administration (FDA).

uniQure N.V. (NASDAQ:QURE) anticipates receiving last minutes wrong 30 days from the pre-BLA gathering and intends to proactively prosecute with the FDA to find an attack toward the accelerated support of AMT-130.

uniQure N.V. (NASDAQ:QURE) specializes successful cistron therapy by processing one-time cistron therapies aimed astatine perchance curing familial and superior diseases.

While we admit the imaginable of QURE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.